These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18697367)

  • 21. p53 and brain tumors: from gene mutations to gene therapy.
    Fulci G; Ishii N; Van Meir EG
    Brain Pathol; 1998 Oct; 8(4):599-613. PubMed ID: 9804370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p53 tumor suppressor: critical regulator of life & death in cancer.
    Fisher DE
    Apoptosis; 2001; 6(1-2):7-15. PubMed ID: 11321044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.
    Harris CC
    J Natl Cancer Inst; 1996 Oct; 88(20):1442-55. PubMed ID: 8841019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53: an overview of over two decades of study.
    Cheah PL; Looi LM
    Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of mutant p53 in human cancer.
    Goh AM; Coffill CR; Lane DP
    J Pathol; 2011 Jan; 223(2):116-26. PubMed ID: 21125670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
    Ooe A; Kato K; Noguchi S
    Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?
    Workman P
    Hum Exp Toxicol; 1995 Feb; 14(2):222-5. PubMed ID: 7779451
    [No Abstract]   [Full Text] [Related]  

  • 29. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours.
    Habib NA; Hodgson HJ; Lemoine N; Pignatelli M
    Hum Gene Ther; 1999 Aug; 10(12):2019-34. PubMed ID: 10466636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 mutations in human head and neck cancer cell lines.
    Kiuru A; Servomaa K; Grénman R; Pulkkinen J; Rytömaa T
    Acta Otolaryngol Suppl; 1997; 529():237-40. PubMed ID: 9288320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
    Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
    Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cancer mutations and normal cell regulation].
    Fredholm BB
    Lakartidningen; 1992 Oct; 89(43):3568, 3571-2. PubMed ID: 1460965
    [No Abstract]   [Full Text] [Related]  

  • 33. [Tumor suppressor genes: mutations in RB and p53 genes are significant carcinogenic factors].
    Wiman KG
    Lakartidningen; 1992 Sep; 89(39):3169-74. PubMed ID: 1405928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour suppressor gene p53 mutation in a case of haemangiosarcoma of a dog.
    Mayr B; Zwetkoff S; Schaffner G; Reifinger M
    Acta Vet Hung; 2002; 50(2):157-60. PubMed ID: 12113170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
    Bykov VJ; Wiman KG
    Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors.
    Li Y; Li B; Li CJ; Li LJ
    Expert Opin Biol Ther; 2015 Mar; 15(3):437-54. PubMed ID: 25496374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 in the diagnosis of human neoplasia.
    Cossman J; Schlegel R
    J Natl Cancer Inst; 1991 Jul; 83(14):980-1. PubMed ID: 2072413
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.
    Purdie CA; Harrison DJ; Peter A; Dobbie L; White S; Howie SE; Salter DM; Bird CC; Wyllie AH; Hooper ML
    Oncogene; 1994 Feb; 9(2):603-9. PubMed ID: 8290271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy.
    Ganly I; Soutar DS; Brown R; Kaye SB
    Br J Cancer; 2000 Jan; 82(2):392-8. PubMed ID: 10646894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.